Streetbeat News

Earnings

EXPE

Expedia Group has revised its full-year guidance downwards due to the underperformance of Vrbo and the current rate of acceleration in its B2C segment. The company now expects mid to high single-digit top-line growth, with margins remaining similar to the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:03 pm

ALHC

Alignment Healthcare (NASDAQ:ALHC) reported Q1 2024 earnings with a GAAP EPS of $(0.25), missing the $(0.22) estimate, and sales of $628.601M, beating the $595.125M estimate. This represents a 25% decrease in EPS and a 43.14% increase in sales year-over-year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:03 pm

AMGN

Amgen projects its FY24 adjusted earnings per share (EPS) to be in the range of $19.00 to $20.20, compared to the estimated $19.48. This forecast suggests a potential for earnings to either exceed or fall short of market expectations.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:03 pm

EXPE

Expedia Group (NASDAQ:EXPE) reported Q1 earnings with losses of $(0.21) per share, surpassing the $(0.24) estimate, and sales of $2.89B, exceeding the $2.81B estimate. This represents a 5% decrease in losses per share compared to last year, but an 8.41% increase in sales from the same period.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:03 pm

HOLX

Hologic, Inc. (NASDAQ:HOLX) reported Q2 2024 adjusted earnings of $1.03 per share, surpassing the consensus estimate of $0.98, and sales of $1.017 billion, also beating the estimate of $1.002 billion. However, both earnings and sales saw a slight decrease compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:02 pm

WSC

WillScot Mobile Mini (NASDAQ:WSC) reported Q1 2024 adjusted EPS of $0.29, missing the consensus estimate of $0.33 by 12.12%. However, their sales of $587.00M exceeded the estimate of $580.95M by 1.04%, marking a 3.81% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:02 pm

BECN

Beacon Roofing Supply reported Q1 sales of $1.91 billion, surpassing the analyst consensus estimate of $1.89 billion by 1.19% and marking a 10.42% increase from $1.73 billion in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:02 pm

AMGN

Amgen reported Q1 2024 adjusted EPS of $3.96, surpassing the $3.87 estimate, with sales of $7.447B also beating the $7.436B estimate. This represents a 21.98% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:02 pm

RARE

Ultragenyx Pharmaceutical projects its FY24 revenue to be between $500M-$530M, which is around the analyst estimate of $513M.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:02 pm

RARE

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported Q1 2024 earnings with a GAAP EPS of $(2.03), missing the $(1.77) estimate, and sales of $108.833M, below the $116.009M estimate. This represents an 8.30% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:01 pm